Subject: DTRA 2006 Medical Science and Technology Chemical and Biological Defense Transformational Medical Technologies Initiatives
ODA
Defense Threat Reduction Agency
Defense Threat Reduction Agency (Headquarters)
A -- 2006 MEDICAL SCIENCE AND TECHNOLOGY (S&T) CHEMICAL AND BIOLOGICAL DEFENSE TRANSFORMATIONAL MEDICAL TECHNOLOGIES INITIATIVE (TMTI)
Modification 02
FYIdue Jan. 3 (
THIS IS A COMBINED SYNOPSIS/SOLICIATION. The purpose of this Broad Agency Announcement (BAA) is to solicit proposals for the Department of Defense (DoD) during Fiscal Year 2006 and possible future years Medical Science and Technology (S&T) Chemical and Biological Defense Transformational Medical Technologies Initiative (TMTI). The DoD conducts a vigorous medical research and development program in chemical and biological defense with the goal of protecting the warfighter from disease and biological and chemical warfare agents.
This BAA is focused on developing medical counter-measures to ermerging threats, genetically engineered and nontraditional toxins, virulence factors and microorganisms as biological warfare (BW) threat agents. An important consideration is a more expedient approach and/or a shorter timeline to advanced development for a potential product. It is anticipated that these counter-measures would include pre-treatments (including vaccine enhancement technology), therapeutics and basic science to characterize the nature of the threat and identify key targets for intervention or disruption of these agents. The agent classes that are to be focused on are: intra-cellular bacterial pathogens, hemorrhagic fever viruses and bioregulators.
Approaches include studying the genetic diversity and pathogenicity of natural isolates, identifying common structural elements of specific agents or classes of agents (preferred), elucidating common virulence mechanisms (such as type III secretory proteins), identifying functional domains in toxins and virulence factors, and using this information to develop rapid and effective medical countermeasures protecting against genetically engineered or emerging BW threats.
2006 MEDICAL SCIENCE AND TECHNOLOGY (S&T) CHEMICAL AND BIOLOGICAL DEFENSE TRANSFORMATIONAL MEDICAL TECHNOLOGIES INITIATIVE (TMTI)
Solicitation 01 - Posted on Oct 31, 2005
General Information
Document Type:
Presolicitation Notice
Solicitation Number:
DTRA01-06-BAA-01
Posted Date:
Oct 31, 2005
Original Response Date:
Jan 03, 2006
Current Response Date:
Jan 03, 2006
Original Archive Date:
Jan 18, 2006
Current Archive Date:
Jan 18, 2006
Classification Code:
A -- Research & Development
Naics Code:
541710 -- Research and Development in the Physical, Engineering, and Life Sciences
Contracting Office Address
Other Defense Agencies, Defense Threat Reduction Agency, Defense Threat Reduction Agency (Headquarters), DTRA Annex 8725 John J. Kingman Road, MSC 6201, Fort Belvoir, VA, 22060-6201
Description
THIS IS A COMBINED SYNOPSIS/SOLICIATION. The purpose of this Broad Agency Announcement (BAA) is to solicit proposals for the Department of Defense (DoD) during Fiscal Year 2006 and possible future years Medical Science and Technology (S&T) Chemical and Biological Defense Transformational Medical Technologies Initiative (TMTI). The DoD conducts a vigorous medical research and development program in chemical and biological defense with the goal of protecting the warfighter from disease and biological and chemical warfare agents. The CBDP seeks to develop counter-measures that can be brought into acquisition and fielded worldwide. These products must be regulatory compliant, robust, and highly effective at a reasonable cost. Successful candidates must demonstrate a clear path to regulatory approval, production and end user utility. They must all be amenable to use in a military environment.
This BAA is focused on developing medical counter-measures to ermerging threats, genetically engineered and nontraditional toxins, virulence factors and microorganisms as biological warfare (BW) threat agents. An important consideration is a more expedient approach and/or a shorter timeline to advanced development for a potential product. It is anticipated that these counter-measures would include pre-treatments (including vaccine enhancement technology), therapeutics and basic science to characterize the nature of the threat and identify key targets for intervention or disruption of these agents. The agent classes that are to be focused on are: intra-cellular bacterial pathogens, hemorrhagic fever viruses and bioregulators.
Approaches to the objectives for this area include studying the genetic diversity and pathogenicity of natural isolates, identifying common structural elements of specific agents or classes of agents (preferred), elucidating common virulence mechanisms (such as type III secretory proteins), identifying functional domains in toxins and virulence factors, and using this information to develop rapid and effective medical countermeasures protecting against genetically engineered or emerging BW threats.
Point of Contact
Katherine Luhmann, Supervisory Contract Specialist, Phone (703) 325-1197, Fax (703) 325-9295, Email - Janice Washington, Contract Specialist, Phone 703-325-9625, Fax 703-325-9295, Email
Place of Performance
Address:
8725 John J. Kingman Road, MS 6201, Fort Belvoir, VA
Postal Code:
22060
Country:
USA